BioCentury
ARTICLE | Company News

Vertex deal

December 20, 1993 8:00 AM UTC

VRTX will develop orally active protease inhibitors to treat HIV and AIDS with Wellcome plc. Wellcome will pay up to $42 million to VRTX, $15 million of which will be an initial payment, as well as research support and milestone payments and will fund all development activities. ...